PepGen Inc Stock Price, News & Analysis

PepGen (Nasdaq: PEPG) will present two oral presentations at the 30th Annual International Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-12, 2025. The presentations will feature previously reported data from two clinical trials:

1. Results from the FREEDOM-DM1 Phase 1 study in myotonic dystrophy type 1 patients, focusing on the 15 mg/kg single dose PGN-EDODM1 cohort, presented by Dr. Hanns Lochmüller on October 11th.

2. Dystrophin results from the CONNECT1-EDO51 Phase 2 study of PGN-EDO51 in Duchenne patients amenable to exon 51 skipping, presented by Dr. Hugh McMillan on October 11th.

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company, has successfully closed its previously announced underwritten public offering of 35,937,500 shares of common stock at $3.20 per share, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of $115 million.

The company plans to use the proceeds to fund ongoing research and clinical development initiatives, specifically the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, along with working capital and general corporate purposes. Leerink Partners and Stifel served as joint bookrunning managers for the offering.

PepGen (NASDAQ: PEPG), a clinical-stage biotechnology company, has announced the pricing of a public offering of 31,250,000 shares of common stock at $3.20 per share, aiming to raise $100 million in gross proceeds.

The offering, expected to close around September 26, 2025, includes a 30-day option for underwriters to purchase up to 4,687,500 additional shares. Leerink Partners and Stifel are serving as joint bookrunning managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, along with working capital and general corporate purposes.

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular and neurological diseases, has announced a proposed public offering of common stock and pre-funded warrants.

The offering includes shares of common stock and pre-funded warrants for certain investors, with a 30-day option for underwriters to purchase additional shares. Leerink Partners and Stifel are serving as joint book-running managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and general corporate purposes.

PepGen (Nasdaq: PEPG) announced groundbreaking clinical data from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) treatment. The company's drug candidate PGN-EDODM1 achieved a remarkable 53.7% mean splicing correction at 15 mg/kg dosing - the highest ever reported in DM1 patients.

The trial demonstrated 100% patient response rate with improved splicing correction. Safety data showed the treatment was generally well-tolerated, with only mild or moderate adverse events. The company previously reported 12.3% and 29.1% splicing correction at 5 mg/kg and 10 mg/kg doses respectively, showing greater than dose-proportional increases.

PepGen plans to report results from its multiple ascending dose (MAD) study's first cohort in Q1 2026.

PepGen (Nasdaq: PEPG) has reported Q2 2025 financial results and corporate updates, highlighting progress in their myotonic dystrophy type 1 (DM1) program. The company has completed patient dosing in the 15 mg/kg cohort of the FREEDOM trial for PGN-EDODM1, with topline data expected in early Q4 2025.

Based on positive splicing correction results and safety data, PepGen will conclude the FREEDOM trial at the 15 mg/kg dose level and transition to FREEDOM2, their Phase 2 multiple ascending dose study. The company expects to report results from the 5 mg/kg cohort of FREEDOM2 in Q1 2026.

Financial highlights include $74.7 million in cash and equivalents as of June 30, 2025, with runway into Q2 2026. Q2 2025 net loss was $23.1 million, or $(0.70) per share, compared to $28.3 million in Q2 2024.

PepGen (NASDAQ: PEPG) announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels in the CONNECT1-EDO51 trial. In the 10 mg/kg cohort (n=4), PGN-EDO51 increased exon 51 skipped transcripts to 4.26% but total dystrophin only reached 0.59% of normal levels. The company will now focus on its promising myotonic dystrophy type 1 (DM1) program, where PGN-EDODM1 has shown encouraging results with 29% mean mis-splicing correction at 10 mg/kg. PepGen expects to report data from the FREEDOM-DM1 15 mg/kg cohort in H2 2025 and from the FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.

PepGen (Nasdaq: PEPG) has appointed Kasra Kasraian, PhD as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations. He joins from bluebird bio, where he most recently served as Senior Vice President of Quality, Regulatory Affairs, and CMC Sciences, playing a key role in the approval and launch of three gene therapy products: SKYSONA™, ZYNTEGLO™, and LYFGENIA™.

Previously, Dr. Kasraian held leadership positions at Zafgen, Biogen, Wyeth Biotech, Pfizer, and Genetics Institute. At Biogen, his CMC team led the submission and approval of 3 BLAs/MAAs. He holds a PhD in Pharmaceutical Sciences and BS in Chemical Engineering from the University of Kentucky.

PepGen (NASDAQ: PEPG) reported Q1 2025 financial results and corporate updates. The company highlighted positive clinical data from its DM1 program, with PGN-EDODM1 showing a mean splicing correction of 29.1% at 10 mg/kg dose. Key upcoming catalysts include data from FREEDOM-DM1's 15 mg/kg cohort (2H 2025) and CONNECT1-EDO51's 10 mg/kg cohort (Q3 2025). Financial highlights show cash position of $97.8 million as of March 31, 2025, with Q1 net loss of $30.2 million ($0.92 per share). R&D expenses increased to $25.4 million from $14.7 million YoY. The company voluntarily paused its Phase 2 CONNECT2-EDO51 trial pending results from CONNECT1's 10 mg/kg cohort. PepGen strengthened its board with two new directors and presented data at major industry conferences.